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Objective: The purpose of this study was to evaluate the impact of various pathologic and
biologic factors in triple-negative breast cancer (TNBC) on chemotherapy response using
in vitro ATP-based chemotherapy response assay (ATP-CRA).
Methods: Forty-seven cases of TNBC were included. Immunohistochemical stains for
androgen receptor (AR), p53, CD10, c-kit, CK5/6, vimentin, bcl-2, E-cadherin, Ki-67 and
epidermal growth factor receptor were performed. In vitro ATP-CRA was used to analyze
chemosensitivity for 5-fluorouracil (5-FU), docetaxel, doxorubicin, epirubicin, vinorelbine,
gemcitabine, methotrexate (MTX), oxaliplatin and paclitaxel.
Results: The results showed that all cytotoxic agents demonstrated the trend that E-cadherin-
expressing cases had a higher cell death rate than E-cadherin-negative cases. Particularly,
vinorelbine showed statistical significance (P ¼ 0.004). Cases with AR expression showed
higher cell death rates than those without in 5-FU and MTX (P ¼ 0.012 and 0.014, respectively).
Conclusions: E-cadherin and AR could be candidate predictive factors for chemotherapy
response in TNBC. Further in vivo study is required to clarify their roles.
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INTRODUCTION
Human breast carcinoma is a heterogeneous tumor that is
diverse in behavior, outcome and response to therapy. A
substantial study to classify heterogeneous breast cancer
has been performed. According to a gene-expression proﬁle
study, it has been divided into ﬁve subtypes with clinical
implications (1–3): luminal A, luminal B, HER-2 overex-
pressing, normal breast-like and basal-like type (triple-
negative phenotype). Previous DNA microarray and
immunohistochemical (IHC) analyses have shown that
80–90% of triple-negative carcinomas are basal-like and
have clinical behavior similar to the basal-like subtype (4).
Triple-negative carcinomas account for 15% of all
invasive ductal carcinomas of no speciﬁc type (5).
Conventional histopathological and molecular analyses of
breast cancers have shown that basal-like tumors are often
high grade (6), have areas of necrosis (7), may have a
typical and atypical medullary phenotype (8) and have a
distinct pattern of genetic alteration (6), including frequent
TP53 mutation (1). The triple-negative phenotype [estrogen
receptor (ER)2 , progesterone receptor (PR)2 and
HER-22] is increasingly used as a surrogate marker for
basal-like breast cancer as those three stains are already
routinely used in the clinical work-up of breast cancer (9).
Although most basal-like tumors do not express ER, PR
and HER-2, some may, and the overlap between basal-like
and triple-negative phenotype is not complete (5).
Triple-negative breast cancer (TNBC) is ER/PR negative
for hormone therapy and HER-2/neu negative for trastuzu-
mab therapy, so these targeted therapies are not very
effective modalities. Standard treatment regimen for TNBC
has not been established, and data about this issue are
insufﬁcient. Surface receptors such as epidermal growth
factor receptor (EGFR), c-kit, protein kinase components of
the mitogen-activated protein kinase pathway and protein
kinase components of the protein kinase B pathway are
suggested as potential therapy targets for TNBC, but these
are under investigation. The present treatment modality for
TNBC is combined chemotherapy, except for surgical treat-
ment. Therefore, the detection of factors that affect chemor-
esponse in TNBC is essential, but the research on this has
not been performed thoroughly.
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The purpose of this study was to evaluate the impact of
various pathologic and biologic factors in TNBC on che-
motherapy response using ATP-CRA.
PATIENTS AND METHODS
PATIENT SELECTION AND CLINICOPATHOLOGIC ANALYSIS
Forty-seven patients newly diagnosed with TNBC between
January 2005 and December 2007 at Yongdong Severance
Hospital, Yonsei University College of Medicine, Seoul,
Korea, were enrolled in this study. TNBC was conﬁrmed by
IHC stains. ER, PR and HER-2 stains were performed. ER
and PR immunohistochemistry signal was evaluated using
the Allred score (10). A score of 0–2 was considered nega-
tive and a score of 3–8 was considered positive. HER-2
staining was scored according to the American Society
of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guideline (11) using the following
categories: 0, no immunostaining; 1þ, weak incomplete
membranous staining in any proportion of tumor cells; 2þ,
complete membranous staining, either non-uniform or weak
in at least 10% of tumor cells; and 3þ, uniform intense
membranous staining in .30% of tumor cells. Cases with
0–1þ were regarded as negative. Only ER-, PR- and
HER-2-negative cases were included in this study. The study
was approved by the Institutional Review Board of Yonsei
University Severance Hospital, and written informed consent
was obtained from all study participants. All patients were
diagnosed as having invasive ductal carcinoma by a pathol-
ogist. All tissues were ﬁxed in 10% buffered formalin and
embedded in parafﬁn. All archival hematoxylin and eosin
(H&E)-stained slides for each case were reviewed by two
pathologists (J.S.K. and W.J.). Histologic grade was assessed
using a modiﬁed Bloom–Richardson classiﬁcation and
nuclear grade was evaluated according to a modiﬁed Black’s
nuclear grade (1, low grade; 2, intermediate grade; and 3,
high grade) (12). Histologic parameters were evaluated from
H&E-stained slides. Clinicopathologic parameters evaluated
in each tumor included patient age at initial diagnosis, sex
and lymph node status.
IHC STAINING
The antibodies used for immunohistochemistry in this study
are shown in Table 1. All immunostainings were performed
using formalin-ﬁxed, parafﬁn-embedded tissue sections.
Brieﬂy, 5 mm-thick sections were obtained with a
microtome, transferred into adhesive slides and dried at
628C for 30 min. After incubation with primary antibodies,
immunodetection was performed with biotinylated antimouse
immunoglobulin, followed by peroxidase-labeled streptavidin
using a labeled streptavidin biotin kit with 3,30-diaminoben-
zidine chromogen as a substrate. The primary antibody incu-
bation step was omitted in the negative control. Slides were
counterstained with Harris hematoxylin. Normal breast
tissues entrapped within the block and appropriate control
tissues were used as positive controls.
INTERPRETATION OF IHC STAININGS
All IHC markers were accessed by light microscopy. Scoring
of immunostained slides was done according to the percen-
tage of tumor cells exhibiting nuclear [androgen receptor
(AR), Ki-67 and p53], nuclear and cytoplasmic (c-kit), cyto-
plasmic (CK5/6, vimentin and bcl-2), and membrane
(E-cadherin and EGFR) staining. The IHC stain results of
AR, p53, CD10, c-kit, CK5/6, vimentin, bcl-2, E-cadherin
and EGFR were considered positive when .10% of tumor
cell nuclei were stained. IHC stain results of Ki-67 were
scored by counting the number of positively stained nuclei
and expressed as a percentage of total tumor cells. These
results were classiﬁed as follows: Group 1, ,10%; Group 2,
10–30%; and Group 3, .30%. All samples were evaluated
without knowledge of ATP-CRA results.
ATP-CRA METHODOLOGY
ATP-CRA was performed as described previously (13).
Tumor tissues were stored in Hanks balanced salt solution
(Gibco BRL, Rockville, MD, USA) containing 100 IU/ml of
penicillin (Sigma, St Louis, MO, USA), 100 mg/ml of strep-
tomycin (Sigma), 100 mg/ml of gentamicin (Gibco BRL),
2.5 mg/ml of amphotericin B (Gibco BRL) and 5% fetal
bovine serum (FBS; Gibco BRL). When required, tissues
were washed, quantitated, minced and then incubated with a
mixture of dispase, pronase and DNase (Sigma) for 12–16 h
at 378C. Isolated cells were separated from tissue fragments
by passing through a cell strainer (BD Falcon, Bedford, MA,
USA). Tumor cells were separated from dead cells and red
blood cells by ﬁcoll (1.077 g/ml) gradient centrifugation at
400 g for 15 min. If a sufﬁcient amount of cells were iso-
lated, blood-derived normal cells were removed using
Table 1. Clone, dilution and source of antibodies used
Antibody Clone Dilution Source
AR AR441 1:100 Lab Vision Corp.
CK5/6 D5/16B4 1:100 DAKO, Denmark
E-cadherin 36B5 1:100 Novocastra, UK
p53 D0-7 1:100 Novocastra, UK
EGFR EGFR.25 1:50 Novocastra, UK
Ki-67 MIB-1 1:150 DAKO, Denmark
bcl-2 3.1 1:50 Novocastra, UK
c-kit Polyclonal 1:100 DAKO, Denmark
Vimentin V9 1:150 DAKO, Denmark
AR, androgen receptor; CK5/6, cytokeratin 5/6; EGFR, epidermal growth
factor receptor.
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anti-CD45 antibody-conjugated magnetic beads (Miltenyi
Biotech, Auburn, CA, USA) (14). The separated tumor cell
preparation was suspended in IMDM (Gibco BRL) including
10% FBS. The cells were then diluted to a cell concentration
between 2000 and 20 000 viable cells/100 ml for plating
onto a 96-well ultra-low attachment microplate (Costar,
Cambridge, MA, USA) with or without anti-cancer drugs
and cultured for 48 h in the CO2 incubator. The cytotoxic
agents selected for assay were those commonly used in the
treatment of breast cancer: 5-ﬂuorouracil (5-FU), docetaxel,
doxorubicin, epirubicin, vinorelbine, gemcitabine, metho-
trexate (MTX), oxaliplatin and paclitaxel.
Treated drug concentrations (TDCs) were determined by
preliminary experiment, which exhibit scattered distribution
of cell death from each specimen (15,16). The TDCs used
were as follows: 5-FU, 50 mg/ml; docetaxel, 3.7 mg/ml; dox-
orubicin, 1.5 mg/ml; epirubicin, 1.2 mg/ml; paclitaxel,
8.5 mg/ml; vinorelbine, 0.18 mg/ml; gemcitabine, 16.9 mg/
ml; MTX, 0.37 mg/ml; and oxaliplatin, 2.9 mg/ml. To
measure ATP level, ATP in the cell lysate was reacted with
luciferin and excessive luciferase (Roche, Mannheim,
Germany) using Victor 3 multilabel counter (PerkinElmer,
Boston, MA, USA). Excel-based raw data were analyzed by
Report Maker version 1.1 (ISU ABXIS, Seoul, Korea).
Brieﬂy, the cell death rate for each drug was calculated as
follows: cell death rate (%) ¼ [1 2 (mean luminescence in
treated group/mean luminescence in untreated controls
group)]  100. To calculate the intra-assay mean coefﬁcients
of variation (CV), luminescence values of each specimen
were measured three to six times in negative and positive
control groups. We then determined whether measured
values at 280 pg of ATP were higher than at 105 pg of ATP.
If microorganism contamination was present, if there was an
inadequate number of cells or if the intra-assay mean CV
exceeded 30, the test concerned was considered a failure. If
measured values in the untreated control group were lower
than in the positive group (105 pg of ATP), the specimen
was considered to have unacceptable viability.
STATISTICAL ANALYSIS
Statistical analyses were carried out using SPSS for
Windows, version 12.0 (SPSS Inc., Chicago, IL, USA).
Statistical signiﬁcance of any differences observed for the
expression of biologic markers in response to different cyto-
toxic drugs was calculated using t-test. Variables having
more than three groups were analyzed with one-way
ANOVA and multiple comparison test using Tukey b.
RESULTS
PATIENT AND TUMOR CHARACTERISTICS
Patient and tumor characteristics are summarized in Table 2.
Forty-seven patients were included in this study. All patients
were women with a mean age of 49.7+ 9.2 years (range,
28–70 years). Forty-two (89.3%) cases were invasive ductal
carcinoma not otherwise speciﬁed (NOS). Medullary carci-
noma in two (4.3%) cases, metaplastic carcinoma in two
(4.3%) and tubular carcinoma in one (2.1%) were included.
Out of 42 cases of invasive ductal carcinoma NOS, 15
(35.7%) patients showed the following histologic features of
basal-like carcinoma: high nuclear and/or histologic grades,
polygonal tumor cells with abundant eosinophilic or clear
cytoplasm, distinct cytoplasmic border, squamoid appear-
ance, large nests with central necrosis and intercellular
eosinophilic materials.
Histologic grade was scored as follows: grade I, 4 (8.5%)
cases; grade II, 14 (29.8%); and grade III, 29 (61.7%). The
number of cases of nuclear grade 1 was 3 (6.4%), nuclear
grade 2 was 11 (23.4%) and nuclear grade 3 was 33
(70.2%). Fifteen (31.9%) cases showed axillary lymph node
metastasis.
IN VITRO DRUG SENSITIVITY OF BREAST CANCER CELLS
BY ATP-CRA
A list of the chemotherapeutic agents tested and their
corresponding results are presented in Table 3. The cell
death rate ranged from 0.0% to 92.9%. The results showed
that paclitaxel had the narrowest range of cytotoxic effects
(0.0–45.0%) with the lowest mean cell death rate (12.9%),
Table 2. Characteristics of TNMC in this study
Parameters Number of patients (n ¼ 47) (%)
Histologic type
Invasive ductal carcinoma, NOS 42 (89.3)
Medullary carcinoma 2 (4.3)
Metaplastic carcinoma 2 (4.3)
Tubular carcinoma 1 (2.1)
Age (years)
,50 24 (51.1)
50 23 (48.9)
Histologic grade
I 4 (8.5)
II 14 (29.8)
III 29 (61.7)
Nuclear grade
1 3 (6.4)
2 11 (23.4)
3 33 (70.2)
Lymph node status
No metastasis 32 (68.1)
Metastasis 15 (31.9)
NOS, not otherwise speciﬁed.
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and doxorubicin had the widest range of cytotoxic effects
(0.0–92.9%). The highest mean cell death rate was noted in
oxaliplatin (34.5%).
CORRELATION BETWEEN ATP-CRA RESULTS AND TUMOR
CLINICOHISTOLOGIC FACTORS
Various clinocohistologic factors (histologic type and grade,
nuclear grade and lymph node status) were analyzed to
assess if there was any association between these factors and
breast cancer cell response to cytotoxic agents. Table 4
shows the correlation between ATP-CRA results and tumor
histologic factor. Cell death rate of all cytotoxic agents
showed no signiﬁcant difference among histologic subtypes.
MTX revealed the highest cell death rates in histologic grade
1 (P ¼ 0.021). Doxorubicin, epirubicin and oxaliplatin
showed the trend of higher histologic grade demonstrating
higher cell death rate. In contrast, 5-FU, paclitaxel and MTX
showed that the lower the histologic grade, the higher the
cell death rate. 5-FU, docetaxel, paclitaxel, vinorelbine
and MTX showed the highest cell death rate in nuclear
grade 1. In contrast, doxorubicin, epirubicin, gemcitabine
and oxaliplatin showed the highest cell death rate in nuclear
grade 3. Doxorubicin, epirubicin, gemcitabine and oxalipla-
tin revealed that the higher the nuclear grade, the higher
the cell death rate. Vinorelbine and MTX showed that
cases with higher nuclear grades demonstrated lower cell
death rates. There was no signiﬁcant difference in cell death
rates between lymph node statuses in all chemotherapeutic
agents.
CORRELATION BETWEEN ATP-CRA RESULTS AND TUMOR
BIOLOGIC FACTORS
The expression of various biologic factors (CK5/6,
E-cadherin, p53, EGFR, vimentin, bcl-2, c-kit, Ki-67 and
AR) as determined by immunohistochemistry was analyzed
to identify any association between these factors and
tumor cell death rates to cytotoxic agents. Table 5 demon-
strates the correlation between ATP-CRA results and
various tumor biologic factors. Seven (14.6%) cases of
TNBC expressed CK5/6. CK5/6-expressed cases showed
higher cell death rates than CK5/6-negative cases in all
cytotoxic agents, except for docetaxel and oxaliplatin.
E-cadherin was expressed in 42 (87.5%) cases. Figure 1
shows cell death rates in cytotoxic agents according to
E-cadherin expression. All cytotoxic agents demonstrated
the trend that E-cadherin-expressed cases had a higher cell
death rate than E-cadherin-negative cases. In particular,
vinorelbine showed statistical signiﬁcance (P ¼ 0.004).
Expression of p53 was noted in 15 (31.3%) patients. There
were inconsistent and variable cell death rates among
cytotoxic agents without signiﬁcant difference according to
p53 status. EGFR was expressed in 20 cases (41.7%). In
paclitaxel, EGFR-negative cases showed higher cell death
rates than EGFR-expressed cases (P ¼ 0.042). 5-FU and
docetaxel demonstrated higher cell death rates in
EGFR-negative cases without statistical signiﬁcance.
Seventeen (35.4%) patients expressed vimentin; however,
there were inconsistent and variable cell death rates among
cytotoxic agents without signiﬁcant difference according to
the status of vimentin expression. bcl-2 was expressed in
seven (14.6%) cases. Except for doxorubicin, epirubicin
and gemcitabine, all drugs showed higher cell death rates
in bcl-2-expressed cases. c-kit was expressed in 12
(25.0%) patients. In 5-FU, cases with c-kit expression
demonstrated higher cell death rate than those without
(P ¼ 0.006). Except for doxorubicin and gemcitabine, all
drugs represented higher cell death rate in c-kit-expressed
cases. Except for gemcitabine and oxaliplatin, all cytotoxic
agents showed the highest cell death rate in group 3 for
Ki-67; however, there was no statistically signiﬁcant differ-
ence. AR was expressed in ﬁve (10.4%) cases. Figure 2
shows cell death rates in cytotoxic agents according to AR
expression. In 5-FU and MTX, patients with AR
expression showed higher cell death rates than those
without (P ¼ 0.012 and 0.014, respectively). TNBC was
classiﬁed into ‘basal-like carcinoma’ and ‘non-basal-like
carcinoma’ according to IHC results for CK5/6, EGFR and
c-kit. Basal-like carcinoma was deﬁned when the case
showed positive expression of CK5/6 or EGFR or c-kit.
Twenty-eight (59.6%) cases were basal-like carcinoma.
Except for 5-FU and docetaxel, higher cell death rates
were noted in basal-like carcinoma than non-basal-like
carcinoma without statistical signiﬁcance.
When ﬁve cases with speciﬁc subtype of medullary,
metaplastic and tubular carcinoma were excluded, there
was also signiﬁcant association between chemosensitivity
of vinorelbine and E-cadherin expression (P ¼ 0.004),
chemosensitivity of 5-FU and AR expression (P ¼ 0.010)
and chemosensitivity of MTX and AR expression
(P ¼ 0.008).
Table 3. In vitro chemosensitivity response of cultured breast cancer cell
lines to a range of cytotoxic drugs according to the ATP-CRA
Cytotoxic drug Rates of cell death (%)
Mean+SD Range
5-Fluorouracil 25.9+12.6 0.0–59.4
Docetaxel 22.5+14.5 0.0–52.7
Doxorubicin 28.8+20.9 0.0–92.9
Epirubicin 32.1+21.7 0.0–90.4
Paclitaxel 12.9+12.6 0.0–45.0
Vinorelbine 31.8+16.8 0.0–61.0
Gemcitabine, 19.9+17.5 0.0–67.0
Methotrexate 21.6+11.7 0.0–45.8
Oxaliplatin 34.5+19.3 0.0–69.0
ATP-CRA, ATP-based chemotherapy response assay.
Jpn J Clin Oncol 2009;39(9) 563
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Table 4. Various tumor clinicohistological factors and ATP-CRA results
Parameter 5-FU
(mean+SD)
Docetaxel
(mean+SD)
Doxorubicin
(mean+SD)
Epirubicin
(mean+SD)
Paclitaxel
(mean+SD)
Vinorelbine
(mean+SD)
Gemcitabine
(mean+SD)
MTX
(mean+SD)
Oxaliplatin
(mean+SD)
Histologic type P ¼ 0.950 P ¼ 0.788 P ¼ 0.798 P ¼ 0.811 P ¼ 0.796 P ¼ 0.950 P ¼ 0.392 P ¼ 0.680 P ¼ 0.936
Invasive ductal
carcinoma, NOS
25.70+13.31 23.11+14.78 29.51+21.95 32.45+22.62 13.44+12.99 32.34+17.12 21.46+17.93 22.15+11.97 35.06+20.15
Medullary
carcinoma
30.50+4.38 16.00+22.62 27.85+4.31 26.25+26.09 4.70+0.00 26.25+26.9 11.70+5.09 17.20+0.00 24.20+0.00
Metaplastic
carcinoma
24.25+6.29 22.15+2.89 26.00+1.41 30.60+15.27 6.25+8.83 30.60+15.27 7.45+2.61 7.90+0.00 27.30+0.00
Tubular carcinoma 29.10+0.00 11.00+0.00 8.10+0.00 26.30+0.00 11.60+0.00 26.30+0.00 0.00+0.00 22.50+0.00 35.80+0.00
Histologic grade P ¼ 0.441 P ¼ 0.284 P ¼ 0.520 P ¼ 0.667 P ¼ 0.995 P ¼ 0.567 P ¼ 0.204 P ¼ 0.021 P ¼ 0.505
I 33.72+11.64 21.12+19.58 18.10+11.01 23.87+11.53 13.52+6.41 31.66+12.45 5.37+7.07 33.57+9.75 22.06+12.31
II 25.60+10.72 17.57+15.51 27.75+20.88 30.77+23.45 12.93+14.04 35.88+16.67 22.92+13.66 25.11+8.85 34.10+24.53
III 24.99+13.64 25.08+13.22 30.83+22.06 33.96+22.19 12.80+12.92 29.61+17.45 20.59+19.45 17.88+11.58 36.19+18.94
Nuclear grade P ¼ 0.848 P ¼ 0.398 P ¼ 0.312 P ¼ 0.223 P ¼ 0.301 P ¼ 0.893 P ¼ 0.340 P ¼ 0.203 P ¼ 0.496
1 28.80+6.85 29.60+18.80 19.10+11.82 19.73+14.01 20.90+9.89 35.23+18.58 5.46+4.99 26.50+5.65 27.10+12.30
2 24.37+12.01 18.00+17.01 22.39+24.01 25.00+25.53 8.81+12.08 33.07+17.05 20.73+14.34 26.26+11.25 28.20+22.43
3 26.19+13.45 23.37+13.36 31.87+20.28 35.67+20.45 13.55+12.85 31.02+17.10 21.06+18.85 18.99+11.80 37.16+18.80
Lymph node status P ¼ 0.683 P ¼ 0.652 0.647 P ¼ 0.084 P ¼ 0.518 P ¼ 0.266 P ¼ 0.318 P ¼ 0.376 P ¼ 0.814
No metastasis 26.44+12.68 23.17+15.48 27.86+19.30 28.40+20.68 13.71+13.61 29.73+16.83 18.22+18.25 22.80+12.88 33.91+19.28
Metastasis 24.80+13.00 21.09+12.64 30.91+24.79 40.15+22.46 11.05+10.20 36.10+16.48 23.76+15.85 18.98+8.43 35.70+20.21
5-FU, 5-ﬂuorouracil; MTX, methotrexate.
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Table 5. Various tumor biologic markers and ATP-CRA results
Parameter Number
(n ¼ 47)
(%)
5-FU
(mean+SD)
Docetaxel
(mean+SD)
Doxorubicin
(mean+SD)
Epirubicin
(mean+SD)
Paclitaxel
(mean+SD)
Vinorelbine
(mean+SD)
Gemcitabine
(mean+SD)
MTX
(mean+SD)
Oxaliplatin
(mean+SD)
CK5/6 P ¼ 0.441 P ¼ 0.544 P ¼ 0.901 P ¼ 0.354 P ¼ 0.831 P ¼ 0.342 P ¼ 0.767 P ¼ 0.079 P ¼ 0.775
Positive 7 (14.6) 29.21+14.31 19.22+13.38 28.85+15.20 37.84+16.60 14.14+13.08 37.70+18.24 21.65+17.43 29.98+13.31 31.00+15.44
Negative 39 (81.3) 25.12+12.55 22.93+14.96 27.80+21.27 29.87+21.28 13.01+12.69 30.91+16.61 19.47+17.94 19.96+11.14 34.48+20.10
E-cadherin P ¼ 0.121 P ¼ 0.051 P ¼ 0.165 P ¼ 0.069 P ¼ 0.095 P ¼ 0.004 P ¼ 0.151 P ¼ 0.642 P ¼ 0.054
Positive 42 (87.5) 26.64+12.58 23.66+14.49 29.25+20.63 32.79+20.52 14.17+12.68 34.69+15.66 20.96+17.89 21.68+12.08 36.80+19.18
Negative 4 (8.3) 16.27+12.03 8.75+8.91 14.40+10.47 13.12+13.64 3.12+6.25 9.70+8.88 7.60+10.01 18.30+9.49 16.75+11.87
p53 P ¼ 0.587 P ¼ 0.656 P ¼ 0.724 P ¼ 0.896 P ¼ 0.589 P ¼ 0.182 P ¼ 0.212 P ¼ 0.817 P ¼ 0.068
Positive 15 (31.3) 24.25+8.07 23.77+13.29 26.41+9.83 30.50+17.57 11.73+11.31 37.26+16.74 24.52+20.07 20.70+13.63 43.28+19.48
Negative 31 (64.6) 26.46+14.55 21.68+15.43 28.71+23.93 31.36+22.29 13.92+13.33 29.56+16.66 17.52+16.27 21.71+11.17 29.56+18.27
EGFR P ¼ 0.059 P ¼ 0.257 P ¼ 0.927 P ¼ 0.937 P ¼ 0.042 P ¼ 0.770 P ¼ 0.235 P ¼ 0.992 P ¼ 0.698
Positive 20 (41.7) 21.71+12.53 19.55+14.25 28.28+20.26 31.36+22.60 8.94+11.22 32.95+16.52 23.37+18.73 21.39+11.80 35.75+20.20
Negative 26 (54.2) 28.85+12.25 24.53+14.87 27.71+20.78 30.86+19.53 16.58+12.83 31.34+17.58 17.06+16.68 21.37+11.11 32.89+19.46
Vimentin P ¼ 0.108 P ¼ 0.685 P ¼ 0.924 P ¼ 0.622 P ¼ 0.339 P ¼ 0.704 P ¼ 0.586 P ¼ 0.331 P ¼ 0.330
Positive 17 (35.4) 21.79+11.62 23.52+13.88 27.58+18.92 29.08+21.26 10.85+9.92 33.45+17.73 21.68+17.64 18.98+11.01 38.45+16.82
Negative 29 (60.4) 28.06+13.00 21.68+15.29 28.18+21.43 32.25+20.61 14.60+13.97 31.30+16.64 18.70+17.93 23.00+12.30 31.25+21.05
bcl-2 P ¼ 0.095 P ¼ 0.071 P ¼ 0.176 P ¼ 0.189 P ¼ 0.252 P ¼ 0.793 P ¼ 0.211 P ¼ 0.183 P ¼ 0.912
Positive 7 (14.6) 33.17+9.39 31.55+14.88 18.32+8.47 21.57+8.44 18.25+10.81 34.27+20.35 12.04+14.06 27.96+9.32 65.04+20.61
Negative 39 (81.3) 24.41+12.90 20.71+14.18 29.69+21.40 32.79+21.80 12.25+12.82 31.88+16.76 21.20+18.06 20.30+11.94 33.95+19.70
c-kit P ¼ 0.006 P ¼ 0.679 P ¼ 0.486 P ¼ 0.140 P ¼ 0.280 P ¼ 0.630 P ¼ 0.775 P ¼ 0.454 P ¼ 0.051
Positive 12 (25.0) 34.30+12.40 20.99+12.95 32.52+25.18 40.18+19.85 16.32+15.96 33.91+15.61 18.72+16.01 24.21+9.47 45.83+19.33
Negative 35 (72.9) 23.04+11.57 23.03+15.17 27.57+19.59 29.40+21.93 11.69+11.24 31.00+17.40 20.42+18.23 20.77+12.42 30.54+18.00
Ki-67 P ¼ 0.447 P ¼ 0.986 P ¼ 0.598 P ¼ 0.331 P ¼ 0.941 P ¼ 0.972 P ¼ 0.770 P ¼ 0.112 P ¼ 0.393
Group 1 17 (36.2) 24.10+10.19 22.55+16.53 28.64+21.10 32.61+23.71 12.93+13.76 31.20+17.22 17.55+17.96 18.16+5.72 27.84+19.46
Group 2 20 (42.6) 24.19+20.59 22.45+13.09 26.15+18.24 27.69+19.56 12.27+11.33 31.76+18.70 21.77+18.02 19.40+16.56 39.04+17.33
Group 3 10 (21.2) 29.07+9.10 22.56+15.20 34.52+26.52 40.31+22.10 14.04+14.14 33.01+13.17 20.58+17.18 27.01+12.35 33.27+23.03
AR P ¼ 0.012 P ¼ 0.859 P ¼ 0.250 P ¼ 0.250 P ¼ 0.190 P ¼ 0.259 P ¼ 0.096 P ¼ 0.014 P ¼ 0.431
Positive 5 (10.4) 39.16+8.68 23.62+21.54 18.54+10.52 21.50+11.20 19.94+12.42 40.90+13.18 7.62+7.19 34.95+9.55 23.90+16.82
Negative 42 (87.5) 24.34+12.19 22.38+13.83 30.06+21.65 33.42+22.41 12.04+12.52 30.79+16.98 21.46+17.87 19.96+10.97 35.22+19.47
IHC subtype P ¼ 0.762 P ¼ 0.213 P ¼ 0.965 P ¼ 0.468 P ¼ 0.814 P ¼ 0.404 P ¼ 0.469 P ¼ 0.466 P ¼ 0.422
Basal-like 28 (59.6) 25.45+14.14 20.32+14.30 28.95+22.50 34.07+22.50 13.26+13.68 33.45+16.09 21.53+18.22 22.79+12.34 36.90+19.59
Non-basal-like 19 (40.4) 26.61+10.45 25.74+14.63 28.66+19.11 29.32+20.82 12.35+11.11 28.74+18.20 17.71+16.71 19.81+10.85 31.15+19.06
IHC, immunohistochemistry.
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DISCUSSION
Studies on detecting factors that affect chemosensitivity in
breast cancer have been extensively performed through
neoadjuvant chemotherapy. Among the known predictive
factors, those that apply to TNBC are ER negativity (17) and
high expression of Ki-67 (18). In previous studies, pre-
operative paclitaxel and doxorubicin chemotherapy showed
that complete pathologic response rate of basal-like cancer
was up to 45% (19), and neoadjuvant anthracycline-based
chemotherapy demonstrated that the clinical response rate of
basal-like cancer was up to 85% (20). However, studies on
predictive factors for chemotherapy response in TNBC have
not been performed. In this study, we investigated various
pathologic and biologic factors to evaluate the effect on che-
mosensitivity in 47 cases of TNBC by using in vitro
ATP-CRA. The results showed that E-cadherin and AR
could be candidate predictive factors in TNBC.
E-cadherin is a transmembrane glycoprotein synthesized
by the CDH1 gene located in chromosome 16q22.1, and its
role is thought to be in cell proliferation, invasion and a
metastasis suppressor (21). E-cadherin inactivation by
mutation, loss of heterozygocity or methylation is character-
istic of invasive lobular carcinoma in the breast. Loss of
E-cadherin is related to larger tumor size, higher tumor
grade, and higher prevalence and metastasis in breast cancer
(22,23). Four (8.3%) cases of TNBC showed loss of
E-cadherin in this study. A previous study showed that
.40% of basal-like and triple-negative phenotypes showed
loss of E-cadherin among non-lobular breast carcinomas,
which was higher than that of other phenotypes (21). The
exact mechanism of E-cadherin loss in basal-like and
triple-negative phenotypes is not known; however, loss of
E-cadherin is suggested to be related to invasion and metas-
tasis pattern, which is characteristic of basal-like and
triple-negative phenotypes (21). In this study, TNBC with
E-cadherin expression showed higher chemoresponse than
TNBC without E-cadherin expression in all chemotherapeu-
tic agents, particularly vinorelbine (P ¼ 0.004). The possible
mechanism that TNBC showing loss of E-cadherin
represented decreased chemosensitivity is thought to be
through epithelial-to-mesenchymal transition. Down-
regulation of E-cadherin expression is known to a hallmark
of epithelial-to-mesenchymal transition (24). Epithelial-to-
mesenchymal transition means that epithelial cells are
dedifferentiated to ﬁbroblastoid migratory cells, and these
mesenchymal cells are thought to be less sensitive to
chemotherapy (25). TNBC is reported to express vimentin,
which is a representative marker of mesenchymal cells (26),
and all four cases with loss of E-cadherin expressed vimen-
tin. These ﬁndings support the above hypothesis. An in vitro
study showed that expression of E-cadherin decreased bcl-2
expression and increased sensitivity to etoposide-induced
Figure 1. Comparison of cell death rates in various cytotoxic agents according to E-cadherin expression. 5-FU, 5-ﬂuorouracil; MTX, methotrexate. *P, 0.05.
Figure 2. Comparison of cell death rates in various cytotoxic agents according to androgen receptor expression. AR, androgen receptor; *P, 0.05.
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apoptosis (27). This could be another possible mechanism of
resistance to chemotherapeutic drugs due to loss of
E-cadherin. However, another in vitro study demonstrated
that tumor cells with E-cadherin expression showed lower
sensitivity to cisplatin than tumor cells without E-cadherin
expression, and that there was no difference in etoposide and
5-FU (28). Therefore, we cannot conclude the effect of
E-cadherin on chemotherapy response yet.
This study demonstrated that patients with AR expression
showed higher cell death rates than those without in 5-FU
and MTX (P ¼ 0.012 and 0.014, respectively). The role of
AR in breast cancer in breast carcinogenesis, and progression
is still uncertain. It has been known that AR shows
expression in 70–90% of invasive breast cancer (29),
lobular carcinoma (30), BRCA-mutated tumor (31) and
mammary Paget’s disease (32). It is known that there is a
relationship between AR and ER/PR status (30,33–36), but a
signiﬁcant percentage of tumors are positive for AR and
negative for ER and PR (34). This ﬁnding represents the
independent expression of AR in human breast cancer.
However, there were divergent data about biologic and clini-
cal signiﬁcation in AR of breast cancer. Univariate analysis
demonstrated that AR showed prognostic power along with
ER, tumor size, tumor grade, lymph node status and high
level of Ki-67 (29). In ER-negative tumors, AR-positive
patients exhibited signiﬁcantly better disease-free survival
than AR-negative tumors (37), and in invasive ductal carci-
noma, AR-positive tumors have been associated with a low
or intermediate histologic grade (30,34,36–38). However,
there was a report that breast cancer with the AR gene or
AR protein showed an increased tendency of axillary lymph
node metastasis (39). In triple-negative carcinoma, especially
lymph node-positive, as expression of AR was lost, there
was an increased incidence of high nuclear grade, develop-
ment of recurrence and distant metastasis. Therefore, AR
could play a role as a prognostic factor in triple-negative car-
cinoma (40). However, a study of AR’s role as a predictive
factor for chemotherapy in breast cancer, particularly TNBC,
has not been performed to our knowledge. In ER, other
hormone receptor-like AR, breast cancer with lower ER
expression was reported to show higher response to che-
motherapy (41), but in other reports, ER-rich tumors showed
higher response to chemotherapy (42). AR expression rate in
this study was 10.4%, which is compatible with that of pre-
vious reports that ranged from 13% to 32% (40,43). The
reason why TNBC with AR expression shows increased che-
mosensitivity in 5-FU and MTX is not known. However, a
possible mechanism is thought to be through the AR signal-
ing pathway. The AR signaling pathway is activated by the
androgen-dependent and -independent pathway (44). We
thought that 5-FU and MTX could inhibit breast cancer cell
proliferation through the AR signaling pathway in TNBC
with AR expression.
The limitation of this study is that it is an in vitro study,
so it could not be concluded that these results would apply
to real patients. However, in a previous breast cancer study,
the chemoresponse results of in vitro ATP-CRA were
consistent with those of real patients at 85% (45). A study
on real patients has its shortcomings as it cannot investigate
the chemoresponse of a single agent due to combined
chemotherapy regimens, but an in vitro study can.
In conclusion, E-cadherin and AR could be candidate pre-
dictive factors for chemotherapeutic drugs in TNBC. Further
in vivo study is required.
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